Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 449 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Malignant Neoplasm in the Liver Clear all
Completed Phase 1 Interventional

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

NCT00441376
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Neoplasms
Interventions
ThermoDox
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT02107755
View directory record Official record
Conditions
Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional

The DRAGON 2 Trial

NCT05428735
View directory record Official record
Conditions
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Interventions
Embolization
Procedure
Lead sponsor
Maastricht University
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Phase 2 Interventional

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT03937830
View directory record Official record
Conditions
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Phase 1 Interventional

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592
View directory record Official record
Conditions
Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
Interventions
vvDD-hIL-2-RG-1
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer

NCT00414492
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
FOLFOX6m, SIR-Spheres microspheres
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002842
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Not applicable Interventional Results available

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

NCT00730483
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
Interventions
PVA microporous hydrospheres/doxorubicin hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Jul 21, 2026, 11:12 AM EDT
Withdrawn Phase 2 Interventional

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645
View directory record Official record
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
ILX-295501
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Stereotactic Radiation Therapy in Treating Patients With Liver Metastases

NCT00567970
View directory record Official record
Conditions
Metastatic Cancer
Interventions
quality-of-life assessment, stereotactic body radiation therapy
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Phase 1 Interventional

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT03860272
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated No phase listed Observational

Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI

NCT00820456
View directory record Official record
Conditions
Colorectal Neoplasm, Hepatic Neoplasm
Interventions
DCE-MRI
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Liver Metastases

NCT00255814
View directory record Official record
Conditions
Metastatic Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 21, 2026, 11:12 AM EDT
Not listed Phase 3 Interventional

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

NCT00039234
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
aldesleukin, histamine dihydrochloride
Biological · Drug
Lead sponsor
Maxim Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Flt3L in Treating Patients With Metastatic Colorectal Cancer

NCT00003431
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
recombinant flt3 ligand
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma

NCT00319683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ADH300004
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 14, 2008 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

NCT01226719
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Panitumumab, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 21, 2026, 11:12 AM EDT
Completed No phase listed Observational

Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases

NCT03401814
View directory record Official record
Conditions
Liver Metastases
Interventions
Magnetic Resonance Elastography
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

NCT06555133
View directory record Official record
Conditions
Colorectal Carcinoma Metastatic in the Liver
Interventions
yttrium-90 radioembolization
Combination Product
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 21, 2026, 11:12 AM EDT